Consumer Goods - Germany



by Hauck Aufhäuser Lamp



EUR 5.00 (old: EUR 5.50)

Temporary struggle, permanent progress; chg.

Progress & outlook on jooli. Launched in the Indian market to capitalize on both lower customer acquisition costs and and a trove of data needed to enhance the app's algorithm, jooli has already witnessed a considerable boost in order volume (+560% in December vs. the previous month), aided by jooliPay. While first KPIs are promising, they are not yet meaningful, and hence we do not expect material top or bottom line contributions from jooli before 2026e, leading us to adjust our estimates accordingly.

FY'23e preview & long-term growth. As we expect Q4 sales to be burdened by the muted consumer sentiment witnessed over the last quarters, and hence softer-than-expected revenues from the holiday season, we trimmed our estimates: Q4 sales are now seen to come in at c. € 11.3m (flat yoy), implying sales of € 44.7m for the full year (-3% yoy; eNuW old: € 45.3m), largely driven by a lower average sales price of € 67 (-7% yoy) as customers postpone big ticket items sales, and only partial recovery of items sold to 168k (+7% yoy). While the weaker-than-expected top line will likely be affected by a weaker-than-expected top line, the company's cost cutting program should continue to bear fruit and thus partially offset a lacking fixed cost coverage. EBIT should hence run to c. € -0.13m for Q4'23 (+89% yoy) and c. € -1.2m for the full year (+17% yoy; eNuW old: € -0.8m).


Convertible bond financing. In Q4'23, elumeo was able to secure a favorable 5-year convertible debt financing of $c. \in 1.2m$ at a 3.8% interest rate from selected suppliers of the company. The out-of-themoney strike price ($\in 4.50$) along with the below-the-market interest rate provide elumeo with a cash infusion that should give elumeo room to maneuver and to focus on its long-term growth initiative #juwe-lo100.

The outlook for the long term remains bright. As the company prepares jooli for a successful roll-out in its European markets, elumeo's core business is well-positioned to capitalize on an eventual recovery of the jewelry and overall e-commerce market, with sales prices and items sold likely to recover to their historical means. Overall, elumeo looks set to grow sales by 7% CAGR to c. € 55m by FY'26e along with reaching a healthy EBIT margin of c. 3% in FY'26e (eNuW), supported by scale efficiencies. Mind you, that positive effects stemming from the jooli roll-out are not reflected in our estimates.

BUY with a changed **PT of € 5.00** based on DCF.

Y/E 31.12 (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	42.4	50.7	45.8	44.7	46.5	49.8
Sales growth	-3.8%	19.5%	-9.5%	-2.6%	4.0%	7.1%
EBITDA	0.6	3.0	-0.5	-0.5	0.5	1.7
Net debt (if net cash=0)	-0.4	-0.6	2.2	3.3	4.5	4.3
FCF	2.2	0.8	-1.5	-1.1	-1.2	0.2
Net Debt/EBITDA	0.0	0.0	-4.8	-6.9	9.3	2.5
EPS pro forma	0.15	2.36	-0.57	-0.21	-0.05	0.17
EBITDA margin	1.5%	5.9%	-1.0%	-1.1%	1.1%	3.4%
ROCE	-0.5%	3.0%	-2.1%	-1.8%	-0.3%	1.5%
EV/sales	0.4	0.3	0.3	0.4	0.4	0.4
EV/EBITDA	27.4	4.6	-34.0	-35.9	37.8	10.7
PER	16.3	1.1	-4.4	-11.8	-50.9	15.2
Adjusted FCF yield	-0.1%	2.7%	-1.8%	-6.5%	-1.0%	5.5%

Source: Company data, NuWays, Close price as of 29.01.2024



Market data	
Share price (in €)	2.62
Market cap (in € m)	14.3
Number of shares (in m pcs)	5.7
Enterprise value (in € m)	18.5
Ø trading volume (6 months)	3,564


	Identifier
Bloomberg Reuters WKN	ELB GR ELB.DE A11Q05
ISIN	DE000A11Q059


Key shareholders				
Freefloat	62.5%			
Blackflint Ltd.	25.8%			
Management	11.7%			


Estimates changes						
	<u>2023e</u>	<u>2024e</u>	<u>2025e</u>			
Sales	-1%	-9%	-17%			
EBIT	-36%	-270%	-34%			
EPS	-34%	-576%	-38%			

Comment on changes

- Reduced FY23 sale to reflect an expected softer Q4 sales development
- Reduced sales estimates for FY24 and beyond as we do not reflect jooli in the numbers anymore until we have a better visibility on the roll-out







Company description

elumeo is a leading company in the area of electronic distribution of high-quality gemstone jewelry making it an affordable luxury for everyone.

Guidance

Update - 02.02.2024



Financials

Profit and loss (EUR m)	2020	2021	2022	2023e	2024e	2025
Sales	42.4	50.7	45.8	44.7	46.5	49.8
Sales growth	-3.8%	19.5%	-9.5%	-2.6%	4.0%	7.19
Cost of sales	20.2	21.8	20.7	21.5	21.2	22.2
Gross profit	22.2	28.9	25.2	23.2	25.2	27.0
Sales and marketing	15.6	18.7	18.0	16.9	17.9	18.7
General and administration	7.0	8.3	8.8	7.9	8.0	8.3
Research and development	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	0.3	0.5	0.6	0.6	0.6	0.0
Other operating expenses	0.2	0.3	0.4	0.1	0.1	0.
Total operating expenses	22.5	26.9	26.6	24.3	25.4	26.
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.
EBITDA	0.6	3.0	-0.5	-0.5	0.5	1.
Depreciation	0.9	1.0	0.9	0.7	0.7	0.
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.
mpairment charges	0.0	0.0	0.0	0.0	0.0	0.
EBIT (inc revaluation net)	-0.3	2.0	-1.4	-1.2	-0.2	1.
nterest income	0.0	0.0	0.0	0.0	0.0	0.
nterest expenses	0.1	0.1	0.1	0.0	0.1	0.
Investment income	0.0	0.0	0.0	0.0	0.0	0.
Financial result	-0.1	-0.1	-0.1	-0.0	-0.1	-0.
Recurring pretax income from continuing operations	-0.4	1.9	-1.5	-1.2	-0.3	0.
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.
Earnings before taxes	-0.4	1.9	-1.5	-1.2	-0.3	0.
ncome tax expense	0.0	-3.5	1.9	0.0	0.0	0.
let income from continuing operations	-0.4	5.4	-3.4	-1.2	-0.3	0.
ncome from discontinued operations (net of tax)	0.6	3.8	0.1	0.0	0.0	0.
Net income	0.2	9.2	-3.3	-1.2	-0.3	0.
Minority interest	0.0	0.0	0.0	0.0	0.0	0.
Net profit (reported)	0.2	9.2	-3.3	-1.2	-0.3	0.
Average number of shares	5.5	5.5	5.5	5.7	5.7	5.
EPS reported	0.04	1.68	-0.59	-0.21	-0.05	0.1
Profit and loss (common size)	2020	2021	2022	2023e	2024e	2025
Sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Cost of sales		43.0%	45.1%	48.1%	45.7%	44.60
.	47.7%	43.070	45.170		45.7 70	44.0
iross profit	47.7% 52.3%	57.0%	54.9%	51.9%	54.3%	55.49
						55.49
Sales and marketing	52.3%	57.0%	54.9%	51.9%	54.3%	55.4 9
Sales and marketing General and administration	52.3% 36.7%	57.0% 37.0%	54.9% 39.2%	51.9% 37.9%	54.3% 38.5%	55.4 9 37.59 16.79
Sales and marketing General and administration Research and development	52.3% 36.7% 16.5%	57.0% 37.0% 16.5%	54.9% 39.2% 19.2%	51.9% 37.9% 17.6%	54.3% 38.5% 17.2%	55.4% 37.5% 16.7% 0.0%
Sales and marketing General and administration Research and development Other operating income	52.3% 36.7% 16.5% 0.0%	57.0% 37.0% 16.5% 0.0%	54.9% 39.2% 19.2% 0.0%	51.9% 37.9% 17.6% 0.0%	54.3% 38.5% 17.2% 0.0%	55.4 9 37.59 16.79 0.09 1.29
Sales and marketing General and administration Research and development Other operating income Other operating expenses	52.3% 36.7% 16.5% 0.0% 0.6%	57.0% 37.0% 16.5% 0.0% 0.9%	54.9% 39.2% 19.2% 0.0% 1.2%	51.9% 37.9% 17.6% 0.0% 1.3%	54.3% 38.5% 17.2% 0.0% 1.2%	55.49 37.59 16.79 0.09 1.29 0.39
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses	52.3% 36.7% 16.5% 0.0% 0.6% 0.4%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3%	55.49 37.59 16.79 0.09 1.29 0.39
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7%	55.4% 37.5% 16.7% 0.0% 1.2% 0.3% 53.4% 0.0%
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0%	55.49 37.59 16.79 0.09 1.29 0.39 53.49 0.09
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1%	55.49 37.59 16.79 0.09 1.29 0.39 53.49 0.09 3.49
Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 2.1%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 1.5%	55.49 37.59 16.79 0.09 1.29 0.39 53.49 0.09 3.49 0.09
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 2.1% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 0.0%	55.49 37.59 16.79 0.09 1.29 0.39 53.49 0.09 3.49 0.09
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets mpairment charges	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 0.0% 0.0%	55.49 37.59 16.79 0.09 1.29 0.39 53.49 0.09 3.49 0.09 0.09
Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net)	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 0.0% 0.0% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 0.0% 0.0% 0.0%	55.44 37.5° 16.7° 0.0° 1.2° 0.3° 53.4° 0.0° 3.4° 1.4° 0.0° 0.0° 0.0°
Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Junusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% -0.7%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 3.9%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% -3.1%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 0.0% 0.0% 0.0% -2.6%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 0.0% 0.0% 0.0% -0.4%	55.44 37.5' 16.7' 0.00' 1.22' 0.33' 53.44' 0.00' 3.44' 0.00' 0.00' 0.00' 0.00'
Sales and marketing General and administration Research and development Other operating income Other operating expenses India operating expenses Junusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets mpairment charges EBIT (inc revaluation net) Interest income Interest expenses	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% -0.7%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 0.0% 0.0% 0.0% 0.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% -3.1% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 0.0% 0.0% 0.0% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 0.0% 0.0% 0.0% 0.0% 0.0%	55.49 37.59 16.79 0.09 1.29 0.39 53.49 0.09 3.49 0.09 0.09 0.09 0.09 0.09
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Junusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% -0.7% 0.0% 0.3%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.0% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 0.0% 0.0% 0.0% 0.0% 0.0%	55.44 37.55 16.75 0.06 1.25 0.35 53.44 0.06 0.09 0.09 0.09 0.09
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Journal or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets mpairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% 0.0% 0.0% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg.	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg.	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0	55.44 37.55 16.75 0.05 1.25 0.35 53.44 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0
Sales and marketing Seneral and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Intancial result Recurring pretax income from continuing operations	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg.	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.0%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 2.1% 0.0% 0.0% 0.0% 0.0% -3.1% 0.0% neg3.2%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% neg.	55.44 37.55 16.75 0.05 1.25 0.35 53.44 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% 0.0% 0.0% -0.7% 0.0% 0.3% 0.0% neg1.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg. 3.8%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg3.2% 0.0%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	55.4' 37.5' 16.7' 0.0' 1.2' 0.3' 53.4' 0.0' 3.4' 1.4' 0.0' 0.0' 2.1' 0.0' 1.2' 0.0' 0.2' 0.0'
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% 0.0% 0.0% -0.7% 0.0% 0.0% neg1.0% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg. 3.8% 0.0% 3.8%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg3.2% 0.0% -3.2%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% 0.0% -2.6% 0.0% 0.0% neg2.7%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	55.44 37.56 16.76 0.06 1.26 0.36 53.44 0.06 0.09 0.09 0.09 0.26 0.09 1.96 0.06
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Fax rate	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% 0.0% -0.7% 0.0% 0.3% 0.0% neg1.0% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg. 3.8% 0.0% 3.8% -183.4%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg3.2% -131.1%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% -2.6% 0.0% 0.1% 0.0% neg2.7% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	55.44 37.56 16.77 0.06 1.26 0.36 53.44 0.06 0.06 0.06 0.06 0.06 1.96 0.06 1.96 0.06
Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Fiax rate Net income from continuing operations	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% 0.0% 0.0% -0.7% 0.0% 0.0% neg1.0% 0.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg3.2% -131.1% -7.4%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% -2.6% 0.0% 0.1% 0.0% neg2.7% 0.0% -2.7%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	55.44 37.56 16.76 0.06 1.22 0.35 53.44 0.06 0.06 0.09 0.09 0.26 0.09 1.99 0.06 1.99
Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income Minority interest	52.3% 36.7% 16.5% 0.0% 0.6% 0.4% 53.0% 0.0% 1.5% 2.2% 0.0% 0.0% -0.7% 0.0% 0.3% 0.0% neg1.0% 0.0% -1.0%	57.0% 37.0% 16.5% 0.0% 0.9% 0.5% 53.1% 0.0% 5.9% 2.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg. 3.8% 0.0% 3.8% -183.4%	54.9% 39.2% 19.2% 0.0% 1.2% 0.9% 58.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.1% 0.0% neg3.2% -131.1%	51.9% 37.9% 17.6% 0.0% 1.3% 0.3% 54.5% 0.0% -1.1% 1.5% 0.0% 0.0% 0.0% -2.6% 0.0% 0.1% 0.0% neg2.7% 0.0%	54.3% 38.5% 17.2% 0.0% 1.2% 0.3% 54.7% 0.0% 1.1% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	44.6% 55.4% 37.5% 16.7% 0.0% 1.2% 0.3% 53.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 1.9% 0.0% 1.9% 0.0%

Net profit (reported)
Source: Company data, NuWays

NuWays AG 2

-7.1%

-2.7%

-0.6%

1.9%

0.5%

18.2%

Update - 02.02.2024



Balance sheet (EUR m)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	3.1	2.5	2.3	2.3	2.4	2.4
Property, plant and equipment	1.5	1.4	0.9	0.9	0.9	0.9
Financial assets	0.1	0.1	0.1	0.1	0.1	0.1
FIXED ASSETS	4.7	3.9	3.3	3.3	3.4	3.4
Inventories	12.1	13.1	13.0	13.8	14.7	15.5
Accounts receivable	1.2	2.3	1.7	1.7	2.0	2.2
Other assets and short-term financial assets	1.0	1.6	1.1	1.1	1.1	1.1
Liquid assets	2.3	2.8	1.4	1.5	0.3	0.5
Deferred taxes	0.0	4.2	2.2	2.2	2.2	2.2
Deferred charges and prepaid expenses	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	16.7	23.9	19.4	20.2	20.2	21.5
TOTAL ASSETS	21.4	27.9	22.7	23.6	23.6	24.8
SHAREHOLDERS EQUITY	4.3	13.7	10.6	9.5	9.2	10.2
MINORITY INTEREST	0.0	0.0	0.6	0.6	0.6	0.6
Provisions for pensions and similar obligations	4.0	0.5	0.0	0.0	0.0	0.0
Other provisions and accrued liabilities	3.8	4.3	2.5	2.5	2.5	2.5
Short-term liabilities to banks	0.5	0.5	0.7	0.7	0.7	0.7
Accounts payable	6.8	5.9	4.9	5.7	5.6	5.9
Advance payments received on orders	0.1	0.1	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	0.4	0.4	0.4	0.4	0.4	0.4
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	7.3	6.5	5.4	6.2	6.1	6.4
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	21.4	27.9	22.7	23.6	23.6	24.8
Palance short (common size)	2020	2021	2022	2023e	2024e	2025e
Balance sheet (common size) Intangible assets	14.6%	8.9%	10.3%	10.0%	10.0%	9.5%
<u> </u>	7.0%	4.9%	4.1%	4.0%	4.0%	3.8%
Property, plant and equipment Financial assets	0.4%	0.3%	0.3%	0.2%	0.2%	0.2%
FIXED ASSETS	22.0%	14.1%	14.7%	14.2%	14.2%	13.5%
Inventories	56.8%	47.1%	57.3%	58.7%	62.1%	62.6%
	5.7%	8.1%	7.5%	7.1%	8.6%	8.8%
Accounts receivable Other assets and short-term financial assets	5.7% 4.7%	5.8%	7.5% 4.8%	4.6%	4.6%	4.4%
		9.9%	6.2%	6.3%	1.2%	2.0%
Liquid assets Deferred taxes	10.8% 0.0%	9.9% 14.9%	9.5%	9.1%	9.1%	2.0% 8.7%
	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred charges and prepaid expenses CURRENT ASSETS	78.0%	85.9%	85.3%	85.8%	85.8%	86.5%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
TOTAL AGGLIG	100.070	100.070	100.0 /0	100.070	100.070	100.0 /0
SHAREHOLDERS EQUITY	20.3%	49.2%	46.7%	40.3%	39.1%	40.9%
MINORITY INTEREST	0.0%	0.0%	2.4%	2.3%	2.3%	2.2%
Provisions for pensions and similar obligations	18.6%	1.7%	0.6%	0.6%	0.6%	0.5%
Other provisions and accrued liabilities	17.7%	15.5%	10.8%	10.5%	10.4%	9.9%
Short-term liabilities to banks	2.4%	1.7%	3.1%	3.0%	3.0%	2.9%
Accounts payable	31.7%	21.3%	21.7%	24.2%	23.9%	23.7%
Advance payments received on orders	0.6%	0.5%	0.2%	0.2%	0.2%	0.2%
Other liabilities (incl. from lease and rental contracts)	1.8%	1.3%	2.0%	1.9%	1.9%	1.8%
Deferred taxes	0.0%	0.0%	0.2%	0.2%	0.2%	0.1%
Deferred income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT LIABILITIES	34.1%	23.2%	23.9%	26.2%	25.9%	25.7%
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company data, NuWays

Update - 02.02.2024



Cash flow statement (EUR m)	2020	2021	2022	2023e	2024e	2025
Net profit/loss	0.3 0.9	5.8	-1.3 0.9	-1.2 0.7	-0.2 0.7	1.
Depreciation of fixed assets (incl. leases)	0.9	1.0 0.0	0.9	0.7	0.7	0.
Amortisation of goodwill & intangible assets						0.
Others	0.0	-0.4	-0.4	0.0	0.0	0.
Cash flow from operating activities	2.4	1.2	-1.4	-0.4	-0.5	0.
Increase/decrease in inventory	1.2	-1.0	0.1	-0.8	-0.8	-0.
Increase/decrease in accounts receivable	-0.2	-1.0	1.3	0.0	-0.4	-0.
Increase/decrease in accounts payable	0.0	-0.8	-0.1	0.8	-0.1	0.
Increase/decrease in other working capital positions	0.9	-0.3	-0.1	0.0	0.0	0.
Increase/decrease in working capital	1.9	-3.2	1.2	0.0	-1.3	-0.
Cash flow from operating activities	2.4	1.2	-1.4	-0.4	-0.5	0.
CAPEX	0.2	0.4	0.1	0.7	0.7	0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0
Financial investments	0.0	0.0	0.0	0.0	0.0	0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0
Cash flow from investing activities	-0.2	-0.4	-0.1	-0.7	-0.7	-0
Cash flow before financing	3.1	1.8	-0.5	-0.4	-0.5	0
· · · · · · · · · · · · · · · · · · ·						
Increase/decrease in debt position	-0.8	0.0	0.6	1.2	0.0	0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0
Capital measures	0.0	0.0	0.0	0.0	0.0	0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0
Others	0.0	-0.4	-0.4	0.0	0.0	0
Effects of exchange rate changes on cash	-0.0	0.0	0.0	0.0	0.0	0
Cash flow from financing activities	-0.8	-0.4	0.1	1.2	0.0	0
Increase/decrease in liquid assets	2.4	1.4	-0.4	0.8	-0.5	0
Liquid assets at end of period	2.3	2.8	1.4	1.5	0.3	0
		-				
Key ratios (EUR m)	2020	2021	2022	2023e	2024e	2025
P&L growth analysis						
Sales growth	-3.8%	19.5%	-9.5%	-2.6%	4.0%	7.1
EBITDA growth	-103.6%	-1100.3%	-172.8%	-116.2%	-205.8%	-454.3
EBIT growth	-98.4%	-184.2%	369.6%	-158.6%	-86.8%	-189.4
EPS growth	-100.9%	-457.5%	-1650.5%	-112.7%	-91.6%	-177.8
Efficiency						
Sales per employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.
EBITDA per employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.
No. employees (average)	0	0	0	0	0	• • • • • • • • • • • • • • • • • • • •
Balance sheet analysis		U	U	U	U	
Avg. working capital / sales	23.0%	18.0%	17.7%	21.4%	22.4%	21.6
Inventory turnover (sales/inventory)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
Accounts receivable turnover	10.6	16.3	13.6	13.6	16.0	16
Accounts payable turnover	122.3	99.5	87.4	96.8	96.8	96
Cash flow analysis						
Free cash flow	2.2	8.0	-1.5	-1.1	-1.2	0
Free cash flow/sales	5.2%	1.6%	-3.2%	-2.5%	-2.6%	0.4
FCF / net profit	763.7%	14.3%	113.5%	97.1%	642.7%	19.9
Capex / sales	0.5%	0.7%	0.1%	1.5%	1.5%	1.4
Solvency						
Net debt	-0.4	-0.6	2.2	3.3	4.5	4
Net Debt/EBITDA	0.0	0.0	-4.8	-6.9	9.3	2
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0
, ,						
Interest paid / avg. debt	6.4%	3.9%	2.6%	1.5%	2.5%	2.2
Returns	0.50/	0.00/	0.407	4.007	0.007	
ROCE	-0.5%	3.0%	-2.1%	-1.8%	-0.3%	1.5
ROE	4.8%	67.4%	-30.6%	-12.7%	-3.1%	9.3
Adjusted FCF yield	-0.1%	2.7%	-1.8%	-6.5%	-1.0%	5.5
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0
DPS	0.0	0.0	0.0	0.0	0.0	0
EPS reported	0.04	1.68	-0.59	-0.21	-0.05	0.1
Average number of shares	5.5	5.5	5.5	5.7	5.7	5
Valuation ratios	5.5	5.5	0.0	5.7	5.7	
P/BV	3.2	1.0	1.3	1.5	1.6	1
EV/sales	0.4	0.3	0.3	0.4	0.4	0
	U.4	0.5	0.5		0.4	
		4.0	240	25.0	270	4^
EV/SAIES EV/EBITDA EV/EBIT	27.4 -58.3	4.6 7.0	-34.0 -11.2	-35.9 -15.0	37.8 -99.8	10 17

Update - 02.02.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
elumeo SE	2,8

Historical target	price and rating changes for	r elumeo SE			
Company	Date	Analyst	Rating	Target Price	Close
elumeo SE	12.11.2023	Jarchow, Frederik	Buy	EUR 5.50	EUR 2.60
	13.08.2023	Jarchow, Frederik	Buy	EUR 5.70	EUR 2.76
	28.07.2023	Jarchow, Frederik	Buy	EUR 5.50	EUR 2.60
	07.07.2023	Jarchow, Frederik	Buy	EUR 6.00	EUR 2.50

Update - 02.02.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed com-

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 02/02/2024 08:13 AM

Date of publication dissemination: 02/02/2024 08:13 AM

Update - 02.02.2024



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow

Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/X



<u>Linkedlı</u>

